Hikal vs Solara Active Pharma Sciences: Share Price, Comparison and Key Differences
- August 12, 2026
- Posted by: Ankit Jaiswal
- Category: News
Hikal MCap Rs 2,800 Cr, loss-making (EPS -2.74, ROE 3.03%). Solara Active Pharma Sciences MCap Rs 2,400 Cr, loss-making (EPS -0.34, ROE -0.12%). Both companies are currently loss-making.
Hikal vs Solara Active Pharma Sciences is a comparison API and specialty chemical investors look up when evaluating two listed Indian companies in the pharma API and crop protection chemical segment. Hikal Limited, a Mumbai-based company, manufactures pharma APIs and crop protection chemicals (herbicides, fungicides) for the global market. Solara Active Pharma Sciences, a Chennai-based company, is an API manufacturer that emerged from Strides-Shasun’s merger and focuses on complex APIs for regulated markets. Both Hikal vs Solara Active Pharma Sciences are currently loss-making – investors should note this prominently before any investment decision.
This Hikal vs Solara Active Pharma Sciences article covers reach and market position, key products, latest declared results and stock valuation. All data is sourced from Groww and public company filings.
Reach and Market Position
In this Hikal vs Solara Active Pharma Sciences comparison, Hikal manufactures pharma APIs and crop protection chemicals for global pharma and agrochemical companies. Market capitalisation is Rs 2,800 Cr.
Click Here – Get Free Investment Predictions
Solara Active Pharma Sciences manufactures complex APIs including ibuprofen, metformin and other regulated-market APIs. Market capitalisation is Rs 2,400 Cr.
Key Products and Business Mix
For the Hikal vs Solara Active Pharma Sciences product breakdown, Hikal: Hikal earns from pharma APIs (antibiotics, antivirals) and agrochemical intermediates. EPS is -Rs 2.74 (loss-making). ROE is 3.03 percent (distorted by small losses). D/E 0.57. Hikal is currently loss-making. Investors should verify current financials before any investment decision.
Solara Active Pharma Sciences: Solara earns from complex pharma APIs for regulated markets. EPS is -Rs 0.34 (loss-making). ROE is -0.12 percent. D/E 0.55. Solara Active Pharma Sciences is currently loss-making. Investors should verify current financials before any investment decision.
Latest Results and Financial Data
On the Hikal vs Solara Active Pharma Sciences results front: Hikal has a market cap of Rs 2,800 Cr and is loss-making with EPS of -Rs 2.74. Hikal is 1.2 times larger than Solara on market cap. Both companies are in a challenging operational phase.
Solara Active Pharma Sciences has a market cap of Rs 2,400 Cr and is loss-making with EPS of -Rs 0.34 and ROE of -0.12 percent. Both Hikal vs Solara are loss-making companies in the API manufacturing segment.
Compare Hikal and Solara Active Pharma Sciences Fundamentals on the Univest Screener
Stock Performance and Valuation
Investors tracking the Hikal vs Solara Active Pharma Sciences comparison should verify current prices on NSE or BSE before trading. The Hikal vs Solara Active Pharma Sciences stock data below reflects the latest available figures from Groww and public company filings.
Hikal vs Solara Active Pharma at current valuations: Both are loss-making. Hikal trades at approximately Rs 2,800 Cr market cap (loss-making). Solara trades at approximately Rs 2,400 Cr market cap (loss-making). The two API companies are similar in market cap size. NEITHER company is profitable at this time – investors should exercise extreme caution.
Hikal vs Solara Active Pharma Sciences: Quick Comparison Table
The comparison table below summarises the key metrics side by side.
| Parameter | Hikal | Solara Active Pharma Sciences |
|---|---|---|
| Sector | Pharma APIs + crop protection chemicals (dual business) | Complex pharma APIs for regulated markets (US, EU exports) |
| Market Cap | Rs 2,800 Cr | Rs 2,400 Cr |
| Profitability | LOSS-MAKING (EPS -2.74) | LOSS-MAKING (EPS -0.34) |
| ROE | 3.03% (distorted) | −0.12% (losses) |
| Debt to Equity | 0.57 | 0.55 |
| Key Products | Pharma APIs + herbicides, fungicides | Ibuprofen, metformin, complex APIs |
| Status | Loss-making phase | Loss-making phase |
Conclusion
The Hikal vs Solara Active Pharma Sciences comparison above covers reach, products, results and valuation. Hikal vs Solara Active Pharma Sciences covers two Indian API manufacturers both currently in loss-making phases. Hikal has pharma API and crop protection chemical businesses. Solara has complex API manufacturing focused on regulated market exports. Hikal vs Solara investors must note that both companies are currently loss-making, and investment decisions should be made with detailed review of each company’s path to profitability, capex cycles and customer contracts. Consult a SEBI-registered advisor before investing in any loss-making company.
Download the Univest iOS App or Univest Android App to track Hikal and Solara Active Pharma Sciences live price and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Is Hikal profitable?
Ans. No. Hikal is currently loss-making with EPS of -Rs 2.74. Investors should verify the latest quarterly results from exchange filings before any investment decision.
Is Solara Active Pharma profitable?
Ans. No. Solara Active Pharma Sciences is currently loss-making with EPS of -Rs 0.34 and ROE of -0.12 percent. Investors should review the latest financials from exchange filings carefully.
What does Hikal make?
Ans. Hikal manufactures pharma APIs for antibiotic and antiviral medicines and crop protection chemicals (herbicide, fungicide intermediates) for global agrochemical companies. It operates from Taloja and Jigani facilities.
What does Solara Active Pharma make?
Ans. Solara Active Pharma Sciences manufactures complex APIs including ibuprofen, metformin and other active ingredients for regulated market pharma companies in the US and Europe.
Are Hikal and Solara in Nifty 50?
Ans. Neither is in Nifty 50. Both are tracked in smaller indices.
Which is larger, Hikal or Solara?
Ans. Hikal at Rs 2,800 Cr is approximately 1.2 times larger than Solara Active Pharma Sciences at Rs 2,400 Cr.
Should I invest in loss-making pharma API companies?
Ans. Loss-making companies carry significantly higher risk than profitable ones. Investors should carefully review the reasons for losses, the path to profitability, management guidance and financial health before investing. Consult a SEBI-registered investment advisor.
